AbbVie suffers fresh setback with lung cancer drug Rova-TAbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer Share XAbbVie suffers fresh setback with lung cancer drug Rova-Thttps://pharmaphorum.com/news/abbvie-suffers-fresh-setback-with-lung-cancer-drug-rova-t/
AbbVie, Pfizer reach licencing agreement for biosimilar HumiraAbbVie has granted a non-exclusive patent license allowing Pfizer to sell its Humira (adalimumab) biosimilar in many countries Share XAbbVie, Pfizer reach licencing agreement for biosimilar Humirahttps://pharmaphorum.com/news/abbvie-pfizer-reach-licencing-agreement-for-biosimilar-humira/
NHS saving £300m with Humira biosimilar dealThe NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of Share XNHS saving £300m with Humira biosimilar dealhttps://pharmaphorum.com/news/nhs-saving-300m-with-humira-biosimilar-deal/
BMS, AbbVie get FDA OK for new myeloma regimenBristol-Myers Squibb and AbbVie have picked up another FDA approval for their multiple myeloma drug Empliciti that they Share XBMS, AbbVie get FDA OK for new myeloma regimenhttps://pharmaphorum.com/news/bms-abbvie-get-fda-ok-for-new-myeloma-regimen/
AbbVie, Roche eye first-line use of Venclexta in leukaemiaAbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into Share XAbbVie, Roche eye first-line use of Venclexta in leukaemiahttps://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/
AbbVie’s CLL drug Venclyxto too expensive for NHS, says NICENICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche’s MabThera/Rituxan (rituximab), is not a cost-effective Share XAbbVie’s CLL drug Venclyxto too expensive for NHS, says NICEhttps://pharmaphorum.com/news/abbvies-cll-drug-venclyxto-too-expensive-for-nhs-says-nice/
Samsung Bioepis’ Humira biosimilar launches in EUSamsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Share XSamsung Bioepis’ Humira biosimilar launches in EUhttps://pharmaphorum.com/news/samsung-bioepis-humira-biosimilar-launches-in-eu/
Billions up for grabs as EU patent on AbbVie’s Humira expiresThe patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a Share XBillions up for grabs as EU patent on AbbVie’s Humira expireshttps://pharmaphorum.com/news/billions-up-for-grabs-as-eu-patent-abbvies-humira-expires/
Sandoz free to launch Humira biosimilar following AbbVie dealNovartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) Share XSandoz free to launch Humira biosimilar following AbbVie dealhttps://pharmaphorum.com/news/sandoz-free-to-launch-humira-biosimilar-following-abbvie-deal/
